Keryx Biopharmaceuticals
Clinical trials sponsored by Keryx Biopharmaceuticals, explained in plain language.
Biopharmaceutical company focused on renal disease treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New hope for kids with kidney disease: drug targets dangerous phosphorus levels
Disease control PausedThis study tests the safety of a drug called ferric citrate in children aged 6 to 17 with chronic kidney disease who have high phosphorus levels. The drug is taken by mouth to help control phosphorus, which can cause bone and heart problems if too high. The study involves 45 chil…
Phase 3 • Sponsor: Keryx Biopharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Iron pill trial for kids with kidney disease pulled before start
Disease control CancelledThis study was designed to test the safety of an iron pill called ferric citrate in children aged 6 to 17 with iron deficiency anemia and chronic kidney disease (not on dialysis). The plan was to compare the iron pill to standard care over 24 weeks. However, the study was withdra…
Phase 3 • Sponsor: Keryx Biopharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC